In vitro and in vivo evidence discourages routine testing and reporting of piperacillin/tazobactam susceptibility of Elizabethkingia species

J Antimicrob Chemother. 2024 Jan 3;79(1):200-202. doi: 10.1093/jac/dkad322.

Affiliations

¹ National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County, Taiwan.
² Institute of Population Health Sciences, National Health Research Institutes, Miaoli County, Taiwan.
³ Department of Pathology, Division of Clinical Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.

No abstract available

MeSH terms

Anti-Bacterial Agents / pharmacology
Drug Therapy, Combination
Flavobacteriaceae Infections*
Humans
Microbial Sensitivity Tests
Penicillanic Acid / pharmacology
Piperacillin / pharmacology
Piperacillin, Tazobactam Drug Combination / pharmacology
beta-Lactamase Inhibitors

Substances

Piperacillin, Tazobactam Drug Combination
Anti-Bacterial Agents
Piperacillin
Penicillanic Acid
beta-Lactamase Inhibitors

Grants and funding